Greatmark Investment Partners Inc. lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 84,010 shares of the company’s stock after selling 1,503 shares during the period. Johnson & Johnson makes up 4.5% of Greatmark Investment Partners Inc.’s portfolio, making the stock its 2nd largest position. Greatmark Investment Partners Inc.’s holdings in Johnson & Johnson were worth $10,190,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Americafirst Capital Management LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth approximately $101,000. Capital Asset Advisory Services LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth approximately $202,000. Stelac Advisory Services LLC acquired a new position in shares of Johnson & Johnson during the first quarter worth approximately $192,000. NewSquare Capital LLC increased its position in shares of Johnson & Johnson by 4.9% in the second quarter. NewSquare Capital LLC now owns 1,791 shares of the company’s stock worth $217,000 after buying an additional 83 shares during the last quarter. Finally, Shayne & CO. LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth approximately $219,000. 65.32% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson (NYSE:JNJ) traded up 0.81% during midday trading on Wednesday, hitting $118.91. 6,337,122 shares of the stock traded hands. The stock has a market cap of $325.32 billion, a price-to-earnings ratio of 22.16 and a beta of 0.61. Johnson & Johnson has a one year low of $89.90 and a one year high of $126.07. The company has a 50-day moving average price of $120.43 and a 200 day moving average price of $116.12.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 19th. The company reported $1.74 EPS for the quarter, beating the Zacks’ consensus estimate of $1.68 by $0.06. The firm had revenue of $18.50 billion for the quarter, compared to the consensus estimate of $17.98 billion. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. Equities research analysts anticipate that Johnson & Johnson will post $6.69 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were paid a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a yield of 2.69%. The ex-dividend date of this dividend was Friday, August 19th. Johnson & Johnson’s dividend payout ratio is currently 60.15%.

A number of analysts recently weighed in on the stock. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 price objective on the stock in a research report on Monday, August 22nd. Leerink Swann reissued an “outperform” rating and issued a $140.00 price objective (up from $125.00) on shares of Johnson & Johnson in a research report on Wednesday, July 20th. Zacks Investment Research lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Tuesday. BTIG Research reissued a “neutral” rating on shares of Johnson & Johnson in a research report on Friday, June 3rd. Finally, RBC Capital Markets reissued an “outperform” rating and issued a $133.00 price objective (up from $125.00) on shares of Johnson & Johnson in a research report on Wednesday, July 20th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating and eleven have given a buy rating to the stock. Johnson & Johnson currently has an average rating of “Hold” and a consensus target price of $119.57.

In related news, CAO Ronald A. Kapusta sold 2,935 shares of the stock in a transaction on Friday, July 22nd. The shares were sold at an average price of $125.01, for a total transaction of $366,904.35. Following the completion of the sale, the chief accounting officer now owns 28,660 shares in the company, valued at approximately $3,582,786.60. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Dominic J. Caruso sold 41,146 shares of the stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the sale, the vice president now owns 157,819 shares of the company’s stock, valued at approximately $19,728,953.19. The disclosure for this sale can be found here. Corporate insiders own 0.11% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.